Fusion Pharmaceuticals
fusion phase actinium based program fusion acquired a phase trial with plan to develop i as a potential first to market activity of in patients who did not respond or progressed on or after agent at | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
9 of 33
Related slides by other companies
MAIA Biotechnology
Investor Presentation
November 2023
robust pipeline | MAIA Biotechnology
MAIA Biotechnology
Investor Presentation
October 2023
robust pipeline | MAIA Biotechnology
MAIA Biotechnology
Investor Presentation
July 2023
robust pipeline thio thio thio first line | MAIA Biotechnology
MindMed
Investor Presentation
April 2021
develop development plan development phase a trial design | MindMed
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights